Washington University’s Institute of Clinical and Translational Sciences supports effort to screen potential COVID-19 antiviral drugs

Washington University School of Medicine postdoctoral researchers Pallavi Chandra, PhD and Ekansh Mittal, PhD

Six months into the pandemic, people diagnosed with mild cases of COVID-19 still are told to isolate themselves and wait out the infection at home. Doctors monitor such patients so they can intervene if their condition deteriorates, but no antiviral drugs have been shown to hasten recovery or forestall severe illness in people who are not sick enough to be hospitalized. Consequently, the hunt is still on for compounds that inactivate the COVID-19 virus and have potential to be developed as antiviral drugs.

Publishing CTSA Program Hub’s Name
CTSA Program In Action Goals
Goal 2: Engage Patients and Communities in Every Phase of the Translational Process
Goal 4: Innovate Processes to Increase the Quality and Efficiency of Translational Research, Particularly of Multisite Trials